Src is the founding member of a diverse family of intracellular tyrosine kinases, and Src has a key role in promoting cancer growth, in part, through its association with receptor tyrosine kinases. However, some Src-related proteins have widely divergent physiological roles, and these proteins include the Rak/Frk tyrosine kinase (Frk stands for Fyn-related kinase), which inhibits cancer cell growth and suppresses tumorigenesis. Rak/Frk phosphorylates and stabilizes the Pten tumor suppressor, protecting it from degradation, and Rak/Frk associates with the retinoblastoma (Rb) tumor suppressor. However, the role of Rak/Frk in receptormediated signaling is largely unknown. Here, we demonstrate that Rak/Frk associates with epidermal growth factor receptor (EGFR), increasing in activity and EGFR binding after EGF stimulation, when it decreases the pool of EGFR present at the plasma membrane. EGFR-Rak binding is direct, requires the SH2 and SH3 domains of Rak/Frk for efficient complex formation and is not dependent on the Grb2 adaptor protein. EGFR mutations are associated with increased EGFR activity and tumorigenicity, and we found that Rak/ Frk associates preferentially with an EGFR exon 19 mutant, EGFRD747-749/A750P, compared with wild-type EGFR. Furthermore, Rak/Frk inhibited mutant EGFR phosphorylation at an activating site and dramatically decreased the levels of EGFRD747-749/A750P from the plasma membrane. Taken together, the results suggest that Rak/Frk inhibits EGFR signaling in cancer cells and has elevated activity against EGFR exon 19 mutants.
INTRODUCTION
Cancer progression is driven by a combined increase in proliferative signals and a decrease in tumor suppressor function. Epidermal growth factor receptor (EGFR) is one of the receptors driving tumor growth in a number of cancers, 1 including lung cancer, and therapeutics targeting EGFR are a promising treatment approach for the disease. 2 Current therapeutics include small-molecule kinase inhibitors, such as erlotinib, and antibody fragments such as cetuximab. [3] [4] [5] EGFR is mutated in a minority of cancer patients, and those with mutations in the ATP binding site have better response to EGFR small-molecule inhibitors, [6] [7] [8] whereas K-Ras mutations correspond with a poor response to the inhibitors.
Upon ligand stimulation, EGFR is internalized through a series of phosphorylation and ubiquitination reactions and either degraded or recycled to the plasma membrane. 9 A number of intracellular sites of EGFR are phosphorylated during this process, and Y1173 is thought to contribute to EGFR internalization 10 and ERK activation, 11 although in some cases Y1173 may also be important in receptor activation. 12 EGFR also associates with Grb2, an SH3-SH2-SH3 (Src homology) adaptor protein, 13 upon EGF stimulation.
14 SH2 domains associate with phosphorylated tyrosine residues, while SH3 domains bind to proline-rich motifs. 15 Many of the binding partners for EGFR during this process have been extensively characterized, but there are significant gaps in our knowledge of the trafficking and recycling of EGFR.
Rak/Frk (Frk stands for Fyn-related kinase) is an Src-related tyrosine kinase [16] [17] [18] [19] containing SH2 and SH3 domains at its amino terminus and a carboxy-terminal tyrosine residue. 20 Unlike many Src-related kinases, which have varying degrees of transforming activity, 20 Rak/Frk is a putative tumor suppressor in breast cancer that arrests cell growth and suppresses tumorigenesis. [21] [22] [23] The apparent mouse homolog of Rak/Frk, called Iyk, 24 is lost in tumors 25 and inhibits cell growth in culture. 26 Iyk is 79% identical to Rak/Frk but has considerable divergence in the amino-terminal SH4 and SH3 domains. 24 In spite of its profound activity in cultured cells, mice lacking Iyk do not form tumors, 27 suggesting that additional tumorigenic events are necessary for Rak/Frk's tumor suppressor function to be detectable in an intact organism.
Rak/Frk binds and phosphorylates the tumor suppressor Pten, 28 stabilizing Pten levels and triggering growth arrest. 23 Many tumor types are deficient in Pten, suggesting that Rak/Frk may have other intracellular functions. Indeed, Rak/Frk binds to the retinoblastoma (Rb) tumor suppressor, 21 although the biological consequences of this interaction are unclear. Rak/Frk also phosphorylates Src on the C-terminal tyrosine of Src, 17 a negative regulatory site, suggesting that Rak/Frk may have broad effects on signaling.
Virtually nothing is known about the role of Rak/Frk in regulating receptor-mediated signaling. Src family kinases, which are structurally similar to Rak/Frk, 17 bind to receptor tyrosine kinases and mediate receptor signaling. In this study, we show that Rak/Frk phosphorylates EGFR on Y1173 and associates with EGFR in punctate intracellular sites, increasing the intracellular pool of EGFR. Furthermore, Rak/Frk preferentially associates with a mutant form of EGFR that is associated with tumor formation. The results suggest that Rak/Frk's tumor-suppressive activities include the downregulation of receptor tyrosine kinases, including EGFR. Figure 1) . EGFR-Y1068 and Y992 are generally associated with activation of the receptor, whereas EGFR-Y1173 phosphorylation has been linked to receptor downregulation. 10, 11, 29 Rak/Frk expression altered EGFR tyrosine phosphorylation in multiple cell lines. In NCI-H226 human squamous cell lung 4) . EGFR-Y1068 phosphorylation was more complex, increasing before EGFR stimulation but decreasing afterwards (Figure 1d, third panel) .
RESULTS
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To determine whether Rak/Frk directly phosphorylated EGFR, or whether the increased phosphorylation occurred through a secondary partner, we tested Rak/Frk activity towards purified, recombinant EGFR 1141-1211 in an in vitro kinase assay. Because the EGFR fusion protein contains two tyrosine residues, phosphorylation was measured by western blot using an EGFR-pY1173-specific antibody, and Rak/Frk efficiently phosphorylated the fusion protein (Figure 1e Figure 3) .
To gain insights into the potential function of the Rak-EGFR complex, we determined the subcellular localization in which the proteins overlap. The localization of Rak/Frk is controversial, having been detected in the nucleus and cytoplasmic puncta. 17, 21, 22 We expressed Rak/Frk in A549 non-small-cell lung cancer cells and detected Rak/Frk in a perinuclear region resembling the endoplasmic reticulum, in cytoplasmic puncta and to a lesser degree at the cell periphery (Figure 3f The Rak/Frk SH2 and SH3 domains collaborate to increase the Rak-EGFR interaction Like other Src-related proteins, Rak/Frk has amino-terminal SH2 and SH3 domains and a carboxy-terminal regulatory tyrosine residue. 17 We deleted the SH2 and SH3 domains, separately or together, and tested co-precipitation with EGFR. Deletion of SH2 and SH3 domains increased Rak-EGFR binding by five-and threefold, respectively (Figure 4a , top panel, plotted in panel b). A western blot of the input lysates for the reactions is shown in the third and fourth panels. In contrast, deletion of both the SH2 and SH3 domains decreased EGFR binding by approximately fourfold (Figure 4c , upper panel, lane 6, summary graph in Figure 4d ), indicating that these domains collaborate to direct Rak-EGFR binding. While deletion of the amino-terminal domains decreased binding, a kinase-deficient mutant (K262R) or mutation of the carboxy-terminal Y497 had little effect on EGFR binding (Figure 4c , lanes 4 and 2, respectively). The kinase-deficient mutant also had no effect on EGFR-Y1173 phosphorylation, while wild-type Rak/Frk increased Y1173 phosphorylation (Supplementary Figure 4) .
EGFR is activated by ligand stimulation, and we determined the extent to which the Rak-EGFR complex changed upon stimulation. EGF increased the levels of Rak/Frk co-precipitating with EGFR by 3.3-fold within 5 min of treatment and remained elevated by 3.4-fold within 30 min (Figure 5a, top panels) . There was also a 27% decrease in Rak/Frk expression after EGF stimulation (Figure 5a, lower panels) . The results suggest that Rak-EGFR binding occurs at the highest levels during the internalization of the receptor. Because Rak/Frk phosphorylates EGFR, we then tested the extent to which Rak/Frk activity is altered by EGF stimulation. At 5 min after EGF stimulation, Rak/Frk activity increased by 2.8-fold (Figure 5b, lane 2) , using an EGFR-Y1173-containing fusion protein as a substrate for an in vitro kinase assay.
One potential mediator of Rak-EGFR binding is the Grb2 adaptor protein, which is predicted to bind to Rak/Frk in protein interaction databases. Indeed, Grb2 co-precipitated (Figure 5c , third panel) with both Rak/Frk and EGFR (Figure 5c , top two panels, lane 2). In contrast, an inactivating Grb2-R86K mutation largely eliminated binding to Rak/Frk and EGFR (Figure 5c , top two panels, lane 3). We posited that Grb2 might act as an adaptor between Rak/Frk and EGFR, but the levels of Rak/Frk coprecipitating with EGFR increased when the inactivating Grb2 mutant was coexpressed with the two proteins (Figure 2d , top panel, compare lanes 2 and 4), suggesting that the Rak-EGFR association is not dependent on Grb2. Because Grb2 binding was not essential for the Rak-EGFR interaction, we tested the possibility that Rak/Frk binds directly to EGFR. A glutathione S-transferase (GST) fusion protein containing amino acids 1141-1121 of EGFR was incubated with Rak/Frk-transfected HEK293 cell lysates and analyzed by western blot. Rak/Frk was readily detected in an affinity precipitation with the EGFR fusion protein (Figure 5e Rak/Frk binding is decreased in an EGFR mutant EGFR is capable of being activated by mutations, including the EGFR-D747-749/A750P mutation in exon 19, 6 which we will refer to as EGFR-D747. Wild type and EGFR-D747 were expressed in MDA-MB-435 melanoma cells, which do not express EGFR (Figure 6a, first panel, lane 1) , and the EGFR-D747 had an elevated (Figure 6b, compare lanes 2 and 3) , and the effect was partially abrogated by EGF stimulation (Figure 6b, lanes 5 and 6) . EGFR-Y1173 phosphorylation was undetectable in this setting.
Because Rak/Frk altered the membrane localization of wild-type EGFR, we considered that it may affect EGFR-D747. Wild-type or mutant EGFR were coexpressed with Rak/Frk, and cell surface proteins were monitored by biotinylation, as in Figure 3 . The total levels of biotinylated proteins in the extract and of wild-type and mutant EGFR were equivalent in the samples ( Supplementary  Figures 5A and B) . Compared to wild-type EGFR, Rak/Frk expression dramatically decreased EGFR-D747 membrane levels (Figure 6c, lanes 5 and 6) . EGFR-D747 was not detected in the unbiotinylated pool, except on very long blot exposures (Supplementary Figure 5C) , possibly because activated EGFR frequently associates with a 'triton-insoluble fraction', 30 and the extraction buffer for the membrane fractionation procedure contains 1% Triton X-100 as detergent. Unlike A549 cells (Figure 3a site and has growth inhibitory, rather than transforming, activity. [21] [22] [23] Src-related kinases play an important role in multiple signaling pathways, including signaling by RTKs. Rak/Frk alters signaling by phosphorylating Pten on Y336, stabilizing Pten levels, 23 but a direct role of Rak/Frk in receptor-mediated signaling is unknown. Here, we demonstrate that Rak/Frk precipitates with EGFR in cancer cells, phosphorylates EGFR directly and alters the pool of EGFR at the plasma membrane.
Rak/Frk expression was very low in lung cancer cell lines, 17 although Rak/Frk RNA is detectable in normal lung. 17 Rak/Frk mutations have also been detected in lung cancer patients, 31 although it is unclear whether heterozygous mutations alone can increase susceptibility to lung cancer. In addition to point mutations, Rak/Frk localizes to chromosome 6q21, a region that is 1 and 4) or plasmids encoding wild-type EGFR (lanes 2 and 5) or EGFR-D747 (lanes 3 and 6). Cells were biotinylated and purified as described in Figure 3 . Intracellular proteins (lanes 1-3) included Rak/Frk and PCNA (lower two panels). EGFR-wildtype localized to the plasma membrane (lane 5), whereas mutant EGFR was not detectable at the extracellular surface when Rak/Frk was expressed (lane 6). (d) MDA-MB-435 cells were transfected with a vector control (lanes 1 and 4) , a plasmid encoding EGFR-D747 (lanes 2 and 5) or plasmid encoding EGFR-D747 and Rak/Frk (lanes 3 and 6). Cells were biotinylated and purified as described in Figure 3 . In the absence of Rak/Frk, EGFR-D747 localized to the plasma membrane (lane 5) and then disappeared from the extracellular surface when Rak/Frk was expressed (lane 6). IB, immunoblotting.
commonly deleted in lung cancers. 32 The Rak/Frk-related Iyk kinase is also frequently lost in cancers. 25 In contrast, the related PTK6/BRK is present in the majority of tumors and has a more complex role in regulating cell growth, 33 in that it inhibits growth of normal epithelial cells 34 38 which is distinct from Rak/Frk. Potential interactions between Rak/Frk and PTK6/Brk are unknown and are the subject of ongoing investigation. In addition to EGFR, we also examined potential interactions between Rak/Frk and Met and did not detect a complex (Supplementary Figure 2) . However, we cannot exclude the possibility that other receptor tyrosine kinases precipitate with Rak/Frk.
We found that individual deletion of the Rak/Frk SH2 or SH3 domains elevates levels of co-precipitating Rak/Frk and EGFR, which suggests that Rak/Frk does not bind to a single phosphorylated tyrosine or proline-rich sequence of EGFR. In contrast, deletion of both domains decreased EGFR binding, suggesting that the Rak/Frk SH2 and SH3 domains function in atypical manner for kinases related to the Src family. Indeed, Src family kinases are activated enzymatically by deletion of their amino-terminal domains, while Rak/Frk enzymatic activity is relatively unaffected. 22 One possible explanation is that the Rak/ Frk SH2 and SH3 domains act as a single entity for some substrates, rather than as individual modules.
We considered the model that the carboxy-terminal tyrosine of Rak/Frk might bind to an adaptor protein, bridging it to EGFR. However, Rak/Frk mutants deleted for the carboxy-terminal tyrosine bind normally to EGFR, which does not support the model. We then tested the hypothesis that Rak/Frk associates with EGFR via an EGFR-Grb2 complex.
1 Indeed, Rak/Frk co-precipitates with wild-type Grb2, and the complex between Rak/Frk and Grb2 was absent when expressing a Grb2 mutant with an inactive SH2 domain ( Figure 5 ), suggesting that the Grb2 SH2 domain is required for Rak/Frk binding. However, Rak/Frk lacks the consensus pY-X-N-X Grb2-SH2 consensus sequence, 39 suggesting that Grb2 may bind indirectly to Rak/Frk through an additional partner. Surprisingly, coexpression of Grb2, Rak/Frk and EGFR had little effect on the levels of the Rak-EGFR complex, and the dominant-negative Grb2 mutant elevated the Rak-EGFR association. We conclude that Rak-Grb2 binding inhibits Rak-EGFR binding, perhaps through competition between the RakGrb2 and Rak-EGFR complexes.
Our results support a model in which Rak-EGFR complexes increase after EGF stimulation. Rak/Frk activity is stimulated by EGF, and Rak/Frk phosphorylates EGFR directly on Y1173 in a biochemical assay. Phosphorylation of EGFR-Y1173 has been associated with increased EGFR uptake, and Rak/Frk hyperexpression decreased EGFR levels at the plasma membrane. In contrast, Rak/Frk decreased the phosphorylation of EGFR-Y1068, a binding site for Grb2, 40 along with Y1086. 41 EGF stimulation increased EGFR-Rak complex formation, Rak/Frk activity and EGFR-Y1173 phosphorylation.
EGFR mutations are frequently activating, drive tumor growth and increase susceptibility of tumors to EGFR inhibitors. 8 The class I EGFR-D747-749/A750P mutant was isolated twice from erlotinibresponding lung cancer patients 6 and is transforming. 42 The EGFR-D747-749/A750P mutant is closely related to the EGFR-D746-750 mutant, 7 which exhibits increased downstream signaling and suppressed ubiquitination and internalization. 43, 44 The regulation of EGFR by ligand binding is complex, involving phosphorylation, ubiquitination and binding of multiple proteins that usher EGFR to endosomes, where it is recycled to the plasma membrane or degraded. 9 Our current model is that increased binding of Rak/Frk to the EGFR-D747-749/A750P mutant may increase endocytosis or slow recycling of the mutant protein. One prediction of this model is that Rak/Frk expression will be attenuated in tumors expressing mutant EGFR, and a test of this hypothesis is in progress.
The colocalization of Rak/Frk and wild-type EGFR in punctate intracellular sites (Figure 3) suggests that it may stabilize or delay the transit of an endosomal population of EGFR. These populations could include newly synthesized EGFR, in transit to the plasma membrane, or endocytosed EGFR. It is unclear whether EGFR exon 19 mutants are trafficked through the same pathways as the wild-type protein or whether Rak/Frk contributes to these pathways. However, our results suggest that Rak/Frk has the potential to attenuate signaling in tumor cells expressing EGFR exon 19 mutants. This may have clinical implications in cancer patients expressing EGFR mutants and may potentially lead to therapeutics targeting the mutant EGFR receptors.
MATERIALS AND METHODS
Cell lines and plasmids A431, A549, BT549, H226, Ovcar-3 and SW-480 cells were obtained from the ATCC (Manassas, VA, USA), cultured under the suggested conditions and verified by Genetica LLC (Cincinnati, OH, USA). MDA-MB-435 melanoma cells were a generous gift from Dr Rina Plattner and Sourik Ganguly. Cells were maintained in Dulbecco's modified Eagle's medium containing 10% serum supreme and antibiotics, except where described. The control and hemagglutinin (HA)-Rak adenoviruses (based on the pShuttle-CMV plasmid) have been described previously. 22 Rak/Frk short interfering RNA was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and was transfected using Oligofectamine (Invitrogen, Grand Island, NY, USA). Purified EGF was from Axcell Biosciences (Newtown, PA, USA).
For the GST-EGFR fusion protein, a polymerase chain reaction product, including the 3421-3633 sequence of the EGFR open reading frame, was amplified using the primers EGFR þ 3421F-Bam (5 0 -AATGGATCCACTGTC CAGCCCACCTG-3 0 ) and EGFR þ 3633R-Xho (5 0 -AATCTCGAGTCATGCTCCAA TAAATTCACTGCT-3 0 ), digested with BamHI and XhoI and cloned into the comparable sites of pGEX-4T-1, forming the plasmid pLJ1. Rak/Frk was myc-tagged by subcloning into the XhoI and NotI sites of the plasmid pCMV-myc-N (BD Clontech, Mountain View, CA, USA) using the plasmid pcDNA3.1-Rak 21 as a template with Rak þ 1F-Xho (5 0 -AATTCTCGAGGTATGA GCAACATCTGTCAGAGG-3 0 ) and Rak þ 1518R-Not (5 0 -AATTGCGGCCGCTCAT CTTATGAAGTTATTTGCATC-3 0 ) as primers, forming the plasmid pLJ3. Rak/Frk mutants lacking the single SH2 and SH3 domains were subcloned using the same approach from the plasmids pGFP-Rak-SH2D and pGFP-Rak-SH3D, 22 forming the plasmids pLJ4 and pLJ5, respectively. The Rak-Y497F and Rak-K262R (KD) mutants were also subcloned similarly from the templates pGFP-Rak-Y497F and pGFP-Rak-KD, 22 forming the plasmids pLJ7 and pLJ6. The Rak/Frk mutant lacking both SH2 and SH3 domains was constructed by amplifying the plasmid pLJ3 with the primers Rak þ 595F-Kpn (5 0 -AATGGTACCGGCCTGTGTGTCAAGCTGGG-3 0 ) and Rak þ 138R-Kpn (5 0 -AATGGTACCGTAGTGCCATGAATCTGTGA-3 0 ), forming the plasmid pLJ8. The pcDNA3.1-Rak-Flag vector has been published previously. 22 The pcDNA3.1-EGFR vector was a gift from Drs Penni Black of the University of Kentucky College of Pharmacy and William Pao of the Vanderbilt University Department of Medicine. The pBabe-EGFR-D747-749/ A750P plasmid was purchased from Addgene (Cambridge, MA, USA). Plasmids were transfected using the Transgin (APSBio, Gaithersburg, MD, USA) reagent following the manufacturer's instructions.
Protein analysis
For immunoprecipitations, cells were lysed in 1% Triton buffer (20 mM HEPES, pH 7.4, 50 mM potassium fluoride (KF), 50 mM b-glycerol phosphate, 150 mM NaCl, 2 mM ethylene glycol tetraacetic acid, 1 mM sodium vanadate, 10% glycerol, 1% Triton X-100 and 1 Â protease inhibitor cocktail (Thermo Scientific, Rockford, IL, USA), and precipitated with antibody and protein A/ G-plus agarose (Santa Cruz Biotechnology). Precipitated proteins were collected by centrifugation and washed five times with 1% Triton buffer. For the first and third washes, pellets were washed with 1% Triton buffer containing 500 mM NaCl. For affinity precipitations with a GST-EGFR fusion protein, 20 mg of GST fusion protein was incubated with 2 mg of cell lysate in 1% Triton buffer and incubated overnight. Centrifuged pellets were then washed three times with 1% Triton buffer, and bound proteins were eluted by boiling in 1 Â sodium dodecyl sulfate-polyacrylamide gel electrophoresis loading buffer.
The antibodies used in the study were anti-Flag (Sigma, St Louis, MO, USA), HA (HA11; BAbCo, Richmond, CA, USA), EGFR (1005; Santa Cruz Biotechnology), anti-EGFR (IMC-C225/Erbitux; ImClone Systems, Branchburg, NJ, USA), EGFR-pY992 (Millipore, Bellerica, MA, USA), EGFR-pY1068 (R&D Systems, Minneapolis, MN, USA), EGFR-pY1173 (Santa Cruz Biotechnology), ku70 (sc-5309; Santa Cruz Biotechnology), anti-Met (C-12; Santa Cruz Biotechnology), antiproliferating cell nuclear antigen (PCNA, PC-10; Santa Cruz Biotechnology) and Rak/Frk (MAB3766; R&D Systems). For western blots of immunoprecipitation reactions of myc-and Flag-tagged proteins, antibodies were biotinylated using the Amersham protein biotinylation system (GE Healthcare, Piscataway, NJ, USA) and western blots were probed with horseradish peroxidase-conjugated streptavidin (Thermo Scientific) at a concentration of 125 ng/ml.
For kinase assays, immunoprecipitated kinases were washed twice with kinase buffer (10 mM HEPES, pH 7.4, 10 mM MgCl 2 and 1 mM dithiothreitol) and resuspended in 30 ml kinase buffer containing 30 mM ATP and 1 mg kinase substrate (GST-EGFR-1141-1211) and incubated at 30 1C for 30 min. The reaction was terminated with lysis buffer containing sodium dodecyl sulfate and boiling before analysis by western blot. To measure cell surface EGFR levels, cells were biotinylated with sulfo-NHS-SS-biotin and purified with avidin-agarose using the Cell Surface Isolation Kit (Thermo Scientific) according to the manufacturer's instructions. In some cases, proteins that remained unbound to the avidin-agarose served as a control for intracellular proteins.
Imaging
For EGFR immunofluorescence, cells were fixed with formaldehyde, permeabilized with Triton X-100 and stained as described previously. 45 However, for Rak/Frk immunofluorescence, cells were permeabilized with methanol. EGFR was stained using the Ab-13 antibody (Thermo Scientific) and Rak/Frk was stained with a monoclonal antibody (MAB3766; R&D). Images were captured on a Leica DM IRBE inverted microscope at the University of Kentucky Imaging Core Facility.
